{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:20:31Z","timestamp":1783405231020,"version":"3.54.6"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014419","name":"EIT Health","doi-asserted-by":"publisher","award":["220720"],"award-info":[{"award-number":["220720"]}],"id":[{"id":"10.13039\/100014419","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Health Serv."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Polygenic risk scores (PRS) offer a novel means of stratifying breast cancer risk, with the potential to personalize screening protocols and measures, and thus improve early detection. However, their implementation in real-world settings remains poorly understood. This study, as part of the BRIGHT project, investigates how PRS-based breast cancer screening is being piloted, adapted, and resisted across five European countries, Estonia, Portugal, Spain, Sweden, and France, drawing on a combination of implementation science and business model theory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We employed a multiple-case study approach, conducting 94 semi-structured interviews with stakeholders across healthcare, policy, industry, and civil society. Analysis was guided by the Value-Information-Process (VIP) framework and complemented by selected constructs from the Consolidated Framework for Implementation Research (CFIR). Data were coded thematically and triangulated with national policy documents, pilot evaluations, and stakeholder workshops.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Implementation trajectories varied significantly across contexts. Estonia demonstrated advanced policy-driven integration enabled by digital infrastructure and centralized governance. Sweden and Spain followed pilot-to-policy models, with strong regional autonomy but slower national uptake. Portugal exhibited market-led adoption driven by private sector innovation, while France pursued a trial-first logic centered on MyPeBS. Common barriers included limited clinical guidelines, low genetic literacy among frontline providers, fragmented IT systems, and slow and unclear Health Technology Assessment (HTA) cycles. Key facilitators included strong institutional alignment, biobank-linked infrastructures, and public trust in preventive care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Successful PRS implementation requires more than scientific validation; it depends on systemic readiness across value narratives, information systems, and governance processes. PRS-based screening thus serves as a test case for the broader challenge of integrating personalized genomics into public health. Findings offer strategic guidance for policymakers, clinicians, and researchers designing future-ready prevention pathways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/frhs.2026.1829295","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:45:22Z","timestamp":1783403122000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementing polygenic risk-based breast cancer screening across European health systems: insights from the BRIGHT project"],"prefix":"10.3389","volume":"6","author":[{"given":"Mario","family":"del Vicario","sequence":"first","affiliation":[{"name":"IESE Business School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Pons Muzzo","sequence":"additional","affiliation":[{"name":"IESE Business School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellie","family":"Harkin","sequence":"additional","affiliation":[{"name":"IESE Business School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Marginet i Assens","sequence":"additional","affiliation":[{"name":"IESE Business School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiwatayo","family":"Lasebikan","sequence":"additional","affiliation":[{"name":"IESE Business School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeme","family":"T\u00f5nisson","sequence":"additional","affiliation":[{"name":"Institute of Genomics, University of Tartu","place":["Tartu, Estonia"]},{"name":"O\u00dc Antegenes","place":["Tartu, Estonia"]},{"name":"Genetics and Personalized Medicine Clinic, Tartu University Hospital","place":["Tartu, Estonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peeter","family":"Padrik","sequence":"additional","affiliation":[{"name":"O\u00dc Antegenes","place":["Tartu, Estonia"]},{"name":"Hematology and Oncology Clinic, Tartu University Hospital","place":["Tartu, Estonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Feldman","sequence":"additional","affiliation":[{"name":"Region Uppsala","place":["Uppsala, Sweden"]},{"name":"Uppsala Health Economics, Department of Public Health and Caring Sciences, Uppsala University","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Sampaio","sequence":"additional","affiliation":[{"name":"Region Uppsala","place":["Uppsala, Sweden"]},{"name":"Uppsala Health Economics, Department of Public Health and Caring Sciences, Uppsala University","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Costa","sequence":"additional","affiliation":[{"name":"Department of Oncology, Unidade Local de Sa\u00fade Santa Maria, Clinical Research Center \u2013 Lisbon Medical Academic Center","place":["Lisbon, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gon\u00e7alo","family":"Nogueira-Costa","sequence":"additional","affiliation":[{"name":"Department of Oncology, Unidade Local de Sa\u00fade Santa Maria, Clinical Research Center \u2013 Lisbon Medical Academic Center","place":["Lisbon, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madli","family":"Tamm","sequence":"additional","affiliation":[{"name":"Institute of Genomics, University of Tartu","place":["Tartu, Estonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Kruuv-K\u00e4o","sequence":"additional","affiliation":[{"name":"O\u00dc Antegenes","place":["Tartu, Estonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Paumard","sequence":"additional","affiliation":[{"name":"IESE Business School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Rosenm\u00f6ller","sequence":"additional","affiliation":[{"name":"IESE Business School"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","volume-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay","year":"2024"},{"key":"B2","year":"2023"},{"key":"B3","year":""},{"key":"B4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","article-title":"Polygenic risk scores for prediction of breast cancer and breast cancer subtypes","volume":"104","author":"Mavaddat","year":"2019","journal-title":"Am J Hum Genet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s12609-024-00533-6","article-title":"Polygenic risk scores for breast cancer","volume":"16","author":"Demarest","year":"2024","journal-title":"Curr Breast Cancer Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41576-018-0018-x","article-title":"The personal and clinical utility of polygenic risk scores","volume":"19","author":"Torkamani","year":"2018","journal-title":"Nat Rev Genet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13073-021-00829-7","article-title":"Polygenic risk scores in the clinic: new perspectives needed on clinical utility","volume":"13","author":"Lewis","year":"2021","journal-title":"Genome Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13058-020-01320-8","article-title":"Integration of polygenic risk scores into breast cancer screening programs","volume":"22","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1470-2045(23)00007-4","article-title":"Polygenic risk scores and breast cancer: clinical utility and ethical considerations","volume":"24","year":"2023","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.3390\/cancers17071056","article-title":"Guidance for the clinical use of breast cancer polygenic risk scores","volume":"17","author":"Padrik","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/11782234231205700","article-title":"Implementation of risk-stratified breast cancer prevention with a polygenic risk score test in clinical practice","volume":"17","author":"Padrik","year":"2023","journal-title":"Breast Cancer: Basic and Clinical Research"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/s41591-021-01549-6","article-title":"Polygenic risk scores and the future of personalized medicine","volume":"27","year":"2021","journal-title":"Nat Med"},{"key":"B13","first-page":"e000554","article-title":"Polygenic risk scores in clinical practice: applications and challenges","volume":"2","year":"2024","journal-title":"BMJ Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1001\/jamaoncol.2018.1901","article-title":"Cost-effectiveness and benefit-to-harm ratio of risk-stratified screening for breast cancer","volume":"4","author":"Pashayan","year":"2018","journal-title":"JAMA Oncol"},{"key":"B15","first-page":"37","article-title":"Attitudes towards risk-stratified breast cancer screening","volume":"60","author":"Manchanda","year":"2016","journal-title":"Eur J Cancer"},{"key":"B16","first-page":"409","article-title":"Personalized prevention in breast cancer","volume":"287","author":"Burton","year":"2020","journal-title":"J Intern Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.clbc.2025.08.021","article-title":"Clinical implementation study of genetic risk-based breast cancer screening","volume":"26","author":"Tamm","year":"2025","journal-title":"Clin Breast Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/S0266462320000215","article-title":"The new definition of health technology assessment: a milestone in international collaboration","volume":"36","author":"O'Rourke","year":"2020","journal-title":"Int J Technol Assess Health Care"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0266462318003720","article-title":"Identifying the need for good practices in health technology assessment","volume":"35","author":"Kristensen","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"key":"B20","year":"2024"},{"key":"B21","year":"2025"},{"key":"B22","year":"2025"},{"key":"B23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/emre.12124","article-title":"Business model implementation within networked enterprises: a case study on a Finnish pharmaceutical project","volume":"15","author":"Solaimani","year":"2017","journal-title":"Eur Manag Rev"},{"key":"B24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1748-5908-4-50","article-title":"Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science","volume":"4","author":"Damschroder","year":"2009","journal-title":"Implement Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13012-015-0242-0","article-title":"Making sense of implementation theories, models and frameworks","volume":"10","author":"Nilsen","year":"2015","journal-title":"Implement Sci"},{"key":"B26","volume-title":"Business Model Generation","author":"Osterwalder","year":"2010"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e044597","DOI":"10.1136\/bmjopen-2020-044597","article-title":"Feasibility and acceptability of personalised breast cancer screening (DECIDO study): protocol of a single-arm proof-of-concept trial","volume":"10","author":"Pons-Rodriguez","year":"2020","journal-title":"BMJ Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/s12885-022-09484-6","article-title":"Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to standard screening in the my personal breast screening (MyPeBS) randomized clinical trial","volume":"22","author":"Roux","year":"2022","journal-title":"BMC Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"100022","DOI":"10.1016\/j.lpmope.2022.100022","article-title":"Recruitment strategy in the MyPeBS randomized study in France","volume":"3","author":"Rouge-Bugat","year":"2022","journal-title":"Presse Med Open."},{"key":"B30","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s12885-025-13848-z","article-title":"Acceptability of risk-based breast cancer screening among professionals contributing to the MyPeBS study","volume":"25","author":"Roux","year":"2025","journal-title":"BMC Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12967-020-02316-w","article-title":"How personalised medicine will transform healthcare by 2030: the ICPerMed vision","volume":"18","author":"Vicente","year":"2020","journal-title":"J Transl Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"A452","DOI":"10.1016\/j.jval.2014.08.1226","article-title":"Economic evaluation in Portugal \u2013 establishment of the national health technology assessment system (sinats)","volume":"17","author":"Cortega\u00e7a","year":"2014","journal-title":"Value Health"},{"key":"B33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12913-022-07489-2","article-title":"The implementation of value-based healthcare: a scoping review","volume":"22","author":"Van den Akker-van Marle","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/eurheartj\/ehae649","article-title":"Clinical utility and implementation of polygenic risk scores for predicting cardiovascular disease: a clinical consensus statement","volume":"46","year":"2025","journal-title":"Eur Heart J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"462","DOI":"10.2471\/BLT.15.155721","article-title":"Priority-setting for achieving universal health coverage","volume":"94","author":"Chalkidou","year":"2016","journal-title":"Bull World Health Organ"},{"key":"B36","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","article-title":"Clinical use of current polygenic risk scores may exacerbate health disparities","volume":"51","author":"Martin","year":"2019","journal-title":"Nat Genet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s41586-019-1310-4","article-title":"Genetic analyses of diverse populations improve discovery for complex traits","volume":"570","author":"Wojcik","year":"2019","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.jacc.2018.07.079","article-title":"Genomic risk prediction of coronary artery disease in 480,000 adults","volume":"72","author":"Inouye","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/eurjpc\/zwaf206","article-title":"Assessing the role of polygenic risk scores in cardiovascular risk prediction: a cross-sectional analysis from the Paracelsus 10,000 cohort","volume":"33","author":"Wernly","year":"2026","journal-title":"Eur J Prev Cardiol"}],"container-title":["Frontiers in Health Services"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frhs.2026.1829295\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:45:24Z","timestamp":1783403124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frhs.2026.1829295\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":39,"alternative-id":["10.3389\/frhs.2026.1829295"],"URL":"https:\/\/doi.org\/10.3389\/frhs.2026.1829295","relation":{},"ISSN":["2813-0146"],"issn-type":[{"value":"2813-0146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1829295"}}